In this article, we are going to take a look at where Apellis Pharmaceuticals (NASDAQ:APLS) stands against other top insider stock buys and sells in January. Ever heard of the “January effect?” ...

In a report released on February 28, Lisa Walter from RBC Capital maintained a Hold rating on Apellis Pharmaceuticals (APLS – Research Report), with a price target of $25.00. The company’s ...

Check Out Our Latest Stock Report on APLS Apellis Pharmaceuticals Stock Performance APLS opened at $26.00 on Tuesday. The company has a debt-to-equity ratio of 1.91, a current ratio of 4.36 and a ...

Apellis Pharmaceuticals Inc (NASDAQ:APLS) is set to release its Q4 2024 earnings on Feb 28, 2025. The consensus estimate for Q4 2024 revenue is $198.35 million, and the earnings are expected to ...

In trading on Friday, shares of Apellis Pharmaceuticals Inc (Symbol: APLS) entered into oversold territory, hitting an RSI reading of 29.0, after changing hands as low as $24.33 per share.

In a report released today, Graig Suvannavejh from Mizuho Securities maintained a Hold rating on Apellis Pharmaceuticals (APLS – Research Report), with a price target of $30.00. See what stocks ...